Otros idiomas Denali Therapeutics Inc.

Acciones

DNLI

US24823R1059

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 29/04/2024			Varia. Cinco días.	Varia. 1 de enero.
15,6 ^USD	+1,10 %		-2,44 %	-27,31 %

09/04	DENALI THERAPEUTICS INC. : UBS da una recomendación de compra	ZM
03/04	Un Insider de Denali Therapeutics vendió acciones por valor de 1.896.250 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04
Denali Therapeutics Files Prospectus for Secondary Offering	22/03
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01/03
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20/02
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	16/02
Sanofi : échec d'un essai de phase 2 contre la SLA	16/02
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	16/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	07/02
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Denali Therapeutics Inc.

Acciones

DNLI

US24823R1059

Otros idiomas

Filtros